	US 11,998,617 B2
	Gene and cell therapy using cell fusion technology
Jung-Joon Sung, Seoul (KR); Seung-Yong Seong, Seoul (KR); Hee-Woo Lee, Seoul (KR); and Ki Yoon Kim, Seoul (KR)
Assigned to CURAMYS INC., Seoul (KR)
Filed by CURAMYS INC., Seoul (KR)
Filed on Jun. 25, 2021, as Appl. No. 17/358,774.
Application 17/358,774 is a continuation of application No. 15/873,488, filed on Jan. 17, 2018, granted, now 11,077,207.
Application 15/873,488 is a continuation in part of application No. PCT/KR2016/007610, filed on Jul. 13, 2016.
Prior Publication US 2021/0322570 A1, Oct. 21, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 48/00 (2006.01); A61K 35/30 (2015.01); A61K 35/545 (2015.01); A61P 21/00 (2006.01); A61P 25/00 (2006.01); C07K 14/005 (2006.01); C12N 5/0735 (2010.01); C12N 5/074 (2010.01); C12N 5/0775 (2010.01); C12N 5/0793 (2010.01); C12N 5/12 (2006.01); C12N 5/16 (2006.01); C12N 9/24 (2006.01); C12N 15/85 (2006.01); A61K 38/00 (2006.01)

CPC A61K 48/005 (2013.01) [A61K 35/30 (2013.01); A61K 35/545 (2013.01); A61P 21/00 (2018.01); A61P 25/00 (2018.01); C07K 14/005 (2013.01); C12N 5/0606 (2013.01); C12N 5/0619 (2013.01); C12N 5/0667 (2013.01); C12N 5/0696 (2013.01); C12N 5/12 (2013.01); C12N 5/16 (2013.01); C12N 9/2402 (2013.01); C12N 15/85 (2013.01); A61K 38/00 (2013.01); C12N 2760/18822 (2013.01); C12N 2760/18833 (2013.01)]

6 Claims

1. A method for alleviating a symptom of a degenerative muscular disease, comprising:

administering to a subject a therapeutically effective dose of mesenchymal stem cells transformed with a vector including genes encoding hemagglutinin neuraminidase (HN) and fusion (F) proteins by an intramuscular route to damaged muscle cells of a subject in need thereof,

wherein the symptom is weakness of muscles.